泰恩康：子公司吲哚布芬片药品注册上市许可申请获受理

Core Viewpoint - The company announced that its wholly-owned subsidiary, Anhui Taienkang Pharmaceutical Co., Ltd., has received a notice of acceptance for the production registration application of Indobufen tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Indobufen tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risk [1] - The medication is indicated for ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - Indobufen tablets can also be used to prevent thrombosis during hemodialysis [1]